-
Mashup Score: 17Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis - 10 month(s) ago
AbstractAims. Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the standard treatment for patients with acute coronary syndrome (AC
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
AbstractAims. Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a clinical entity with several causes and pathophysiologic mechanisms. Se
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Ultra-Processed Foods Consumption Increases the Risk of Hypertension in Adults: A Systematic Review and Meta-Analysis - 1 year(s) ago
AbstractBackground. Effect of ultra-processed foods (UPFs) consumption on health has attracted widespread attention in recent years. However, the relationship b
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4
AbstractObjective. To evaluate the specific effects of PCSK9 inhibitors (i.e. alirocumab and evolocumab) on major cardiovascular events (MACE) and lipid profile
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 47
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3-year follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not o …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0What We’re Reading: Health Insurers to Cut PA Process; Bipartisan Bill to Stop MA Overpayments; J&J Ends RSV Vaccine Work - 1 year(s) ago
Payers are looking to roll back on paperwork requirements for prior authorization (PA); CMS and Medicare Advantage (MA) insurers battle over new regulations; Johnson & Johnson (J&J) falls behind Pfizer and GSK for vaccine approval.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 15
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3 years follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5
GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6
GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3 years follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
#DAPT de-escalation in acute coronary syndrome: an individual patient #MA https://t.co/ZVEL5UmjKj